Evidence map›Paper›PMID 40764819›Full record

Observational studyScientific reports2025

Multicentre retrospective observational study for development and validation of MAC prognostic score model.

Kazuaki Takeda, Takahiro Takazono, Shotaro Ide, Masataka Yoshida, Naoki Iwanaga, Naoki Hosogaya, Yusei Tsukamoto, Satoshi Irifune, Takayuki Suyama, Tomo Mihara and 17 more

Abstract readMulticenter StudyObservational StudyValidation Study
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Kazuaki TakedaDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. takahiro-takazono@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-0696-5386
Shotaro IdeDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Masataka YoshidaDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Naoki IwanagaDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Naoki HosogayaClinical Research Center, Nagasaki University Hospital, Nagasaki, Nagasaki, Japan.
Yusei TsukamotoDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Satoshi IrifuneDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Takayuki SuyamaDepartment of Respiratory Medicine, Nagasaki Gotochuoh Hospital, Goto, Nagasaki, Japan.
Tomo MiharaDepartment of Respiratory Medicine, Japan Community Health Care Organization Isahaya General Hospital, Isahaya, Nagasaki, Japan.
Akira KondoDepartment of Respiratory Medicine, NHO Nagasaki Medical Center, Omura, Japan.
Tsutomu KobayashiDepartment of Respiratory Medicine, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan.
Yuichi FukudaDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Nagasaki, Japan.
Eisuke SasakiDepartment of Respiratory Medicine, NHO Ureshino Medical Center, Ureshino, Saga, Japan.
Toyomitsu SawaiDepartment of Respiratory Medicine, Nagasaki Harbor Medical Center, Nagasaki, Nagasaki, Japan.
Yasuhito HigashiyamaDepartment of Internal Medicine, Hokusho Central Hospital, Sasebo, Nagasaki, Japan.
Kohji HashiguchiDepartment of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Minako HanakaRespiratory Medicine, Iizuka Hospital, Iizuka, Fukuoka, Japan.
Toshihiko IiDepartment of Respiratory Medicine, NHO Miyazaki Higashi Hospital, Miyazaki, Japan.
Kiyoyasu FukushimaDepartment of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Isahaya, Nagasaki, Japan.
Kosaku KomiyaRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Yufu, Oita, Japan.
Taiga MiyazakiDivision of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Kazuhiro YateraDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Koichi IzumikawaDepartment of Infectious Diseases, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Akitsugu FurumotoInfectious Diseases Experts Training Center, Nagasaki University Hospital, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global incidence and mortality rates of Mycobacterium avium-intracellulare complex pulmonary disease (MAC-PD) are increasing. We conducted a multicentre retrospective cohort study across 18 hospitals to develop a scoring system for predicting respiratory infection-related mortality in patients with MAC-PD. A total of 1,165 patients newly diagnosed with MAC-PD between 2010 and 2017 were enrolled and randomly allocated to a 4:1 ratio to derivation (n = 932) and validation (n = 233) groups. Among them, 656 patients (56.3%) received MAC-PD treatment within 5 years. During the observation period, all-cause mortality occurred in 183 patients (15.7%), and respiratory infection-related mortality occurred in 67 patients (5.8%). To identify the risk factors for respiratory infection-related mortality, Cox proportional hazards analysis was conducted in the derivation group, which informed the development and validation of the prognostic scoring model. Five independent risk factors were identified: age ≥ 65 years, male sex, interstitial pneumonia, albumin < 3.5 g/dL, and cavitary lesions. A prognostic score was developed by assigning 2 points to albumin < 3.5 g/dL and 1 point to each of the other factors. The score demonstrated good predictive performance, with areas under the receiver operating characteristic curves of 0.86 and 0.81 in the derivation and validation groups, respectively. Patients with scores ≥ 3 had significantly poorer prognoses than those with scores ≤ 2. The strength of this study lies in its multicentre validation and focus on respiratory infection-related mortality, providing a clinically useful risk stratification tool for MAC-PD.

Indexed as

Mycobacterium avium ComplexMycobacterium avium-intracellulare InfectionAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsRespiratory Tract InfectionsRetrospective StudiesRisk FactorsROC CurveMAC prognostic scoreMycobacterium avium–intracellulare complexPrediction modelRetrospective study

Identifiers

PMID40764819
PMCPMC12325584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.